“SOUL Trial: Oral Semaglutide and MACE Reduction Cardiovascular protection from an oral GLP-1 in high-risk type 2 diabetes” (2026) Diabzen, 4(19), pp. 38–39. Available at: https://www.thediabzen.com/index.php/d/article/view/62 (Accessed: 17 September 2026).